Linda Bain Adds to Arvinas, Inc. Holdings on NasdaqGS

On June 24, 2026, Linda Bain made a significant move by purchasing 15,527 shares of Arvinas, Inc. (NasdaqGS: ARVN). This insider transaction took place as the stock traded near $8.03.

Insider Buying and Selling at Arvinas, Inc.

Linda Bain wasn't the only insider making moves at Arvinas on June 24. Edward Moore Jr., Laurie Smaldone Alsup, Briggs Morrison, and Leslie Norwalk also bought shares on the same day. Each of these insiders acquired 15,527 shares, with Morrison making an additional purchase of 22,714 shares. These transactions were not part of any pre-planned trading program.

Other Institutional Activity in Arvinas, Inc.

BlackRock, Inc. reduced its holdings in Arvinas by 524,917 shares, leaving it with 6,797,584 shares valued at approximately $72.1 million. Vanguard Portfolio Management LLC opened a new position with 3,889,628 shares worth about $41.2 million. D. E. Shaw & Co., Inc. slightly trimmed its stake by 50,634 shares, ending with 3,638,567 shares valued at around $38.6 million. Pfizer Inc. maintained its position with 3,457,815 shares valued at $34.9 million. Meanwhile, Vanguard Capital Management LLC also initiated a new position with 2,689,362 shares worth approximately $28.5 million.

Arvinas, Inc. Stock Down 12.9%

Shares of Arvinas, Inc. traded near $8.03 on Saturday. The company, with a market cap of about $518 million, operates in the biotechnology sector. The stock has a 52-week low of $6.06 and a high of $14.51. It has a beta of 1.745, indicating relatively high volatility. The 50-day moving average is $9.08, and the 200-day moving average is $10.67. Arvinas has a strong current ratio of 5.44 and a quick ratio of 5.36, with a debt-to-equity ratio of 2.17.

Analysts Set New Price Targets

Analysts remain optimistic about Arvinas, Inc. On June 3, 2026, Stephens & Co. reiterated a 'buy' rating with a price target of $18. Barclays maintained its 'buy' rating with a $20 target on May 13. BTIG also maintained a 'buy' rating, setting a target of $18 on the same day. Citigroup has consistently maintained a 'buy' rating, with its latest target set at $24 on May 4. The consensus among 15 analysts is a 'buy' recommendation, with a mean target price of $14.80.

About Arvinas, Inc.

Arvinas, Inc., based in New Haven, Connecticut, is a clinical-stage biotechnology company. It focuses on the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company utilizes its proprietary PROTAC technology to target and degrade specific proteins involved in various diseases, including cancer and neurodegenerative disorders. Founded in 2013, Arvinas collaborates with major pharmaceutical companies like Pfizer and Genentech.

Bottom Line

Linda Bain's recent purchase of Arvinas shares highlights insider confidence in the biotechnology company's prospects. Investors often monitor such transactions for potential insights into a company's future. While insider activity can be telling, it's important to remember that these trades are disclosed after the fact and may not reflect current positions. As always, investors should consider multiple factors when evaluating a stock.